STAT News

STAT+: GSK sees its return to cancer start to pay off

A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.

By STAT News

1 min read
STAT+: GSK sees its return to cancer start to pay off
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights